http://www.fool.com/investing/dividends-income/2007/07/23/boston-scientific-still-drowsy.aspx

Ryan Fuhrmann, CFA
July 23, 2007

Medical device firm Boston Scientific (NYSE: BSX) recently regained consciousness, but its recovery remains far from certain. The company still hasn’t followed through on the initial hype from last year’s acquisition of archrival Guidant.

Read the rest of this entry »

http://www.fool.com/investing/general/2007/04/24/boston-scientific-regains-consciousness.aspx

Ryan Fuhrmann, CFA
April 24, 2007

For the most part, medical device maker Boston Scientific (NYSE: BSX) is still reeling from drug-eluting stent challenges and difficulties encountered after boldly acquiring rival Guidant last April. A full recovery may be some time off, but a couple of positive signs are beginning to surface.

Read the rest of this entry »

http://www.fool.com/investing/general/2007/02/05/boston-scientifics-unscientific-outlook.aspx

Ryan Fuhrmann, CFA
February 5, 2007

To the victor go the spoils, or so it’s said. Unfortunately, Boston Scientific‘s (NYSE: BSX) success in winning Guidant from the clutches of Johnson & Johnson (NYSE: JNJ) has so far only spoiled billions of dollars in shareholder capital. Management is still optimistic it will have the last laugh, but when might that be?

Read the rest of this entry »

http://www.fool.com/news/mft/2006/mft06102017.htm

By Ryan Fuhrmann, CFA
10/20/2006

On Wednesday, Boston Scientific(NYSE: BSX) reported third-quarter results that were at the upper end of the company’s late-September earnings warning. The shares have had a rough run lately, down nearly 40% over the past year. Buying opportunity? Hard to tell at this point.

Read the rest of this entry »